Dr. Puri is a pharmacist by education, and a pharmaceutical business executive by training and experience. After earning his MS and PhD in Pharmaceutics, Dr. Puri worked for several years at Baxter Healthcare Corp and Amgen Inc., in the areas of parenteral drug development and drug delivery.
Dr. Puri founded InnoPharma, Inc. in 2005 with a focus on developing complex generic pharmaceuticals of sterile injectable dosage forms. This business model was targeted to provide options to health care providers and patients for some of the products where no generic option was available, primarily attributed to complexity of developing and manufacturing the drug products.
Between 2005 and 2014, InnoPharma, Inc. grew as a major player in generic injectable space, with numerous approved and filed generic products that had very limited competition in the marketplace. InnoPharma, Inc. was acquired by Pfizer in Sept 2014 and became an integral part of Pfizer’s Global Establish Pharma business thereafter. Dr. Puri stayed with Pfizer, following acquisition, as President InnoPharma, Inc. – a Pfizer Company and VP of Pfizer’s Worldwide R&D, and left Pfizer in July 2015.
Dr. Puri received Smart CEO award by Future 50 magazine in Jan 2015. He was also awarded E&Y Entrepreneur of the year award from the state of NJ, in June 2015.
Mr. Ramanathan is a Pharmacist by education with over 20 years of experience in the pharmaceutical industry. Mr. Ramanathan has a Master’s degree in Pharmaceutical Sciences and a Master’s degree in Business Administration.
Prior to joining Nevakar, LLC, Mr. Ramanathan was the Chief Operating Officer at InnoPharma, Inc. a pharmaceutical development company focused on the development of complex generic sterile products. He continued with InnoPharma as Executive Director, Operating Officer after the acquisition of the company by Pfizer, Inc. in September 2014 and left InnoPharma, Inc. – a Pfizer Company in November 2015.
Mr. Ramanathan held various positions within the US pharmaceutical industry, including Roche Vitamins Inc., Inhale Therapeutics (now Nektar Therapeutics), Alpharma and Cardinal Health. His professional experience and expertise ranges from R&D, process development, regulatory affairs and operations, as well as management of projects through development, regulatory filing and commercialization.
Dr. Trillo is a physician by education and anesthesiologist by specialization. He has over 25 years of healthcare experience having held clinical and commercial positions of increasing responsibility in specialty pharmaceuticals, medical devices, biologics, and healthcare provider services. Commercial experience includes products sold in anesthesia, critical care, cardiology, surgery, immunology, nutrition, oncology, immunology, and hemophilia.
Prior to joining Nevakar, Dr. Trillo spent a significant portion of his career at Baxter International where he held corporate, regional, and country leadership roles in medical affairs, marketing, strategy, and general management. He has led sales and marketing efforts that have resulted in the successful launch and relaunch of hospital products as well as leading important initiatives in business integration, business development, commercial development, portfolio optimization, and product lifecycle management.
Most recently, Dr. Trillo was CEO of Lexington Healthcare Network, a $200M privately-held post-acute care provider with approximately 3000 employees and services that included rehabilitation, skilled nursing, homecare, hospice, and telemedicine.
Dr. Trillo graduated summa cum laude from Columbia College, Columbia University with honors that included induction into Phi Beta Kappa. He obtained his medical degree at the University of Pennsylvania. His medical internship and anesthesia training were conducted at the Hospital of the University of Pennsylvania. He obtained subspecialty training in pediatric anesthesia at the Children’s Hospital of Philadelphia. He has an MBA from Columbia Business School graduating with honors that included election into Beta Gamma Sigma.
Dr. Soppimath is a graduate in Pharmaceutical Science from the Karnatak University Dharwad, India where he also obtained his PhD with research focus on Nano and micro particle drug delivery systems. Dr. Soppimath also received his MBA from the Martin Tuchman School of Management, NJIT.
Dr. Soppimath has over 15 years experience working in the pharmaceutical and drug delivery industry. He has worked for several pharmaceutical companies including Cadila Pharmaceuticals, Sun Pharmaceuticals, Western Center for Drug Development, Semler Research Center and InnoPharma, Inc.
Before joining Nevakar, LLC, Dr. Soppimath was heading the formulation development team at InnoPharma, Inc. where he strategized and developed more than 20 complex injectable and ophthalmic products. Dr. Soppimath has more than 25 research articles, several granted patents and patent applications to his credits.
Mr. Woodworth has more than 25 years of experience in financial roles of increasing responsibility including over 20 years of experience in life sciences and related sectors. Prior to joining Nevakar, Marshall held CFO roles with Braeburn Pharmaceuticals Inc., Aerocrine AB and Furiex Pharmaceuticals Inc.
During his career, Marshall has worked for a number of companies including: Eli Lilly, Dow Chemical, Monsanto, and Milliken. Marshall brings a wealth of experience in private and public company management and stewardship and has extensive experience working with investors and analysts in the life science sector.
Throughout his career, Marshall has contributed to the success of companies by acting as a key resource and advisor to management, working closely with R&D and operations, and ensuring that finance functions are informed by a deep understanding of programmatic operations.
Marshall holds a BS degree from the University of Maryland College Park and an MBA from Indiana University in Bloomington.
Mr. Shetty holds a Bachelor of Pharmacy from Poona College of Pharmacy, MS in Pharmacy Administration, MS in Management Information Systems from the University of Illinois at Chicago and an MBA from the Lake Forest Graduate School of Management.
Mr. Shetty has over 15 years of extensive experience in market research, portfolio management, marketing, product launches, business development and strategic planning with various pharmaceutical companies in the global injectable pharmaceutical space.
Prior to joining Nevakar, LLC, Mr. Shetty was VP of Business Development and Alliance Management at InnoPharma, Inc. Mr. Shetty held various management positions with Fresenius Kabi, APP Pharmaceuticals, Baxter and Hospira. While at APP Pharmaceuticals Mr. Shetty had marketing responsibility for the critical care portfolio of over $400 Mil.
Mr. Shetty has held key strategic roles at Hospira and Fresenius Kabi that has helped achieve short and long term business objectives.
Dr. Larkin has 25 years of clinical experience as a board-certified emergency physician. Dr. Larkin obtained the rank of Professor early in his career along with other academic accolades including Masters degrees in chemical engineering, molecular biology, biostatistics and clinical research design.
Dr. Larkin is a prolific clinician scholar with over 150 publications, 20 book chapters, and over 5000 citations. Professor Larkin publishes widely on research ethics and he authored the Principles of Ethics for Emergency Physicians and the Code of Conduct for Academic Emergency Medicine, both global standards.
Prior to joining Nevakar, Dr. Larkin served as the inaugural Lion’s Chair of Emergency Medicine at University of Auckland and the inaugural professor in emergency medicine at Yale University. He currently serves as an Adjunct Professor of Psychiatry at New York University School of Medicine.
Professor Larkin has received research grant support from various NIH institutes including NIAAA, NIDA, and NHLBI as well as numerous foundations and governmental funding bodies. He has been awarded a number of distinctions, including a recent nomination for the Asia Pacific Healthcare Clinical Innovation Award (APAC 2015), election to the International Academy of Suicide Research, and a Distinguished Investigator Research Award from the American Foundation for Suicide Prevention. He won the prestigious Atlantic Fellowship in Public Policy with HMS Government in Whitehall under Prime Minister Tony Blair. He continues to advise the NHS and the World Health Organization (WHO) on global health issues related to injury/trauma, mental health, toxicology, and complex humanitarian disasters
Mr. Kappelhof is a Mechanical Engineer by training, earned his Masters in Business Administration with a focus on Strategic Management from the University of Strathclyde in Glasgow, United Kingdom, and is a certified Project Management Professional.
Prior to joining Nevakar, Mr. Kappelhof led the Portfolio and Project Management organization at Daiichi-Sankyo Pharma Development, following a successful career at Schering-Plough Corporation, Pfizer Inc. and Pharmacia Inc. Mr. Kappelhof brings over 20 years of experience in Portfolio and Program Management in Pharmaceutical Development across a wide range of therapeutic areas.
During his career he led and built state of the art Global Portfolio and Project Management organizations and has extensive direct experience providing project management leadership to numerous early and late stage clinical development programs, including successful registration of multiple new therapies in all major global markets.
Reema earned her BS and MS degrees in Food Science from Rutgers University. She began her career as a Scientist at National Starch & Chemical Company then moved on to Technical Sales with Henkel. In 2009, Reema joined InnoPharma, Inc. as the HR & Project Manager where she supported InnoPharma’s growth by leading its talent recruitment and retention efforts, overall HR operations and affairs, as well as facilities management. She was also responsible for setting up IP Pharma, a subsidiary of InnoPharma, Inc., in Bangalore, India.
Reema has been engaged in Nevakar, LLC since its formation as the Vice President, HR by providing overall HR support, talent recruitment, as well as managing facilities and office administration.
Dr. Da Silva is a microbiologist by training, having earned her Masters and Ph.D degrees in Microbiology and Microbial Genetics from the University of Lausanne, Switzerland. She worked as a scientist for more than a decade before pursuing her career in Regulatory Affairs.
Before joining Nevakar, Dr. Da Silva was Executive Director and regulatory team leader in the Internal Medicine group at Daiichi-Sankyo Pharma Development. Prior to that Dr. Da Silva held key strategic roles at Pfizer Inc. where she had regulatory responsibilities for a billion-dollar CV portfolio, and at Acorda Therapeutics.
Dr. Da Silva has over 15 years’ experience working in Regulatory Affairs across a wide range of therapeutic areas, covering projects from early development through registration and into post-approval. She has led efforts that have culminated in new registrations and new indications in the US and globally, and has extensive experience managing regulatory and compliance activities for approved drugs.
Dr. Cammack provides overall strategic direction and coordination of activities at Nevakar to ensure compliance with GLP, GCP and GMP regulations, and other applicable global regulatory requirements and Quality and Compliance Standards. He is responsible for developing and aligning the Quality strategy with Nevakar’s business objectives.
Prior to joining Nevakar, Jon was Global Vice President of Development Quality for AstraZeneca’s biotech businesses. There, he was responsible for strategic oversight for all biologics R&D Quality operations, including combination products and biosimilars. Jon has over 20 years of commercial and development experience with medical products, including leadership roles in large and small pharma/biotech companies, and as a co-founder of a risk
management consulting company. He holds advisory board positions at Northwestern University’s Center of Excellence in Nanotechnology Cancer Research, and the Biotechnology program at the University of Illinois Medical School. Jon received a B.S. in Chemistry from University of Central Missouri, and a Ph.D. in Pharmacology from University of Kansas.